BACKGROUND: Recent failures of drugs that raised high-density lipoprotein (HDL) cholesterol levels to reduce cardiovascular events in clinical trials have led to increased interest in alternative indices of HDL quality, such as cholesterol efflux capacity, and HDL quantity, such as HDL particle number. However, no studies have directly compared these metrics in a contemporary population that includes potent statin therapy and low low-density lipoprotein cholesterol.
High-density lipoprotein (HDL) cholesterol is a well-integrated biomarker of cardiometabolic health and remains a key component of the cardiovascular disease (CVD) risk prediction algorithms used to guide therapy. 1 However, HDL cholesterol-raising therapeutics have failed to demonstrate efficacy in multiple recent clinical trials. [2] [3] [4] These results have called into question both the causality of the observed relationship between HDL and CVD and the hypothesis that modulation of HDL cholesterol levels can improve clinical outcomes. At a minimum, it has become clear that changes in HDL cholesterol levels are an inadequate surrogate biomarker for therapeutic efficacy.
The static measurement of HDL cholesterol levels, as is performed in current clinical practice, may not adequately capture the anti-atherogenic properties of highly heterogeneous HDL particles. Beyond apolipoprotein A-I (apoA-I), proteomics analyses have identified >80 distinct proteins associated with circulating HDL particles. 5 Previous studies have suggested that the number of circulating HDL particles may serve as a better predictor of cardiovascular risk than HDL cholesterol levels. [6] [7] [8] [9] [10] [11] [12] [13] A putative atheroprotective mechanism of HDL involves the reverse cholesterol transport pathway, the process by which excess cholesterol is removed from the periphery and returned to the liver for biliary excretion.
14 Cholesterol efflux capacity is 1 metric of HDL functionality that quantifies the ability for an individual's HDL to extract cholesterol from macrophages, the rate-limiting step of reverse cholesterol transport. Efflux capacity was demonstrated to be a better predictor of atherosclerotic burden than HDL cholesterol levels in several previous studies. [15] [16] [17] [18] [19] This inverse relationship was extended to incident cardiovascular events in some [16] [17] [18] but not all 19 previous analyses. However, owing to challenges of standardizing a cell-based assay across laboratories, it is unlikely that assessment of efflux capacity will enter into routine clinical use. Few previous studies have determined the relationships among these various HDL-related biomarkers, and none to date have directly compared their associations with incident cardiovascular events, particularly in a contemporary cohort with low or normal levels of low-density lipoprotein (LDL) cholesterol levels that includes randomized treatment with potent statin therapy. Here, we examined prospective associations of HDL cholesterol, apoA-I, HDL particle number, and cholesterol efflux capacity in a nested case-control cohort derived from the JUPITER trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin). 20 
METHODS

Study Population
The study population was derived from the JUPITER trial, a previously reported primary prevention, randomized, double-blind, placebo-controlled trial investigating whether rosuvastatin 20 mg daily would decrease incident CVD in 17 802 asymptomatic individuals with LDL cholesterol <130 mg/dL and a high-sensitivity C-reactive protein (hsCRP) level ≥2.0 mg/L. 20 Exclusion criteria for the JUPITER trial included diabetes mellitus, previous or current use of lipid-lowering therapy, or triglycerides >500 mg/dL. In addition to blood samples required for the trial protocol assays, 11 953 (67%) of trial participants voluntarily provided samples for additional biomarker phenotyping. End points within the JUPITER trial were adjudicated by an independent committee blinded to treatment assignment. 20 All participants provided written informed consent as part of the JUPITER trial enrollment. Institutional review board approval for the present study was obtained from Partners HealthCare (Boston, MA) .
A nested case-control cohort was derived from individuals with available baseline blood samples. The primary analysis involved 314 cases who experienced the JUPITER trial primary end point (myocardial infarction, hospitalization for unstable angina, arterial revascularization, stroke, or cardiovascular death); an expanded secondary end point (N=525 cases) was prespecified to additionally include death from any cause as
Clinical Perspective
What Is New?
• Moderate correlations between high-density lipoprotein (HDL)-related biomarkers-HDL cholesterol, apolipoprotein A-I, HDL particle number, and cholesterol efflux capacity-were noted in JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) participants, reinforcing the complementary information provided by each assessment. • No significant relationship was observed between baseline or serial changes in cholesterol efflux capacity (a commonly used measure of HDL functionality) and incident cardiovascular events. However, cholesterol efflux capacity assessed on potent statin therapy was inversely associated with incident cardiovascular events.
• Among HDL-related biomarkers, HDL particle number demonstrated the strongest inverse association with incident cardiovascular events when assessed at both baseline and on potent rosuvastatin therapy.
What Are the Clinical Implications?
• Cholesterol efflux capacity was a marker of residual risk when assessed on statin therapy, consistent with a potential role in driving residual risk in a low low-density lipoprotein cholesterol environment.
• HDL particle number was a stronger predictor of cardiovascular disease than other HDL-related biomarkers and may serve as a biomarker of residual risk or response to therapy in the future.
• Whether a therapy designed to enhance cholesterol efflux capacity or increase HDL particle number can reduce cardiovascular risk remains uncertain.
implemented in previous JUPITER biomarker analyses (Table  I in the online-only Data Supplement) . [21] [22] [23] Each case definition was compared to controls who remained free of events at the time of case event and matched in a 1:1 ratio based on age (±2 years) and sex.
Laboratory Measurements
Fasting lipids, apolipoproteins, hsCRP, and glucose levels were measured in a core laboratory as previously described. 20, 23, 24 HDL particle number was measured using nuclear magnetic resonance spectroscopy LipoProfile III by LipoScience, Inc. (now LabCorp). Total particle number was calculated to be the sum of levels across HDL subclasses, identified based on lipid methyl group nuclear magnetic resonance signals as previously described. 12 Cholesterol efflux capacity was quantified in plasma samples thawed from liquid nitrogen storage using a previously validated cell-based ex vivo assay. 15 In brief, J7774 macrophage cells were incubated with 3 H-radiolabeled cholesterol. Expression of the ATP-binding cassette transporter A1 transporter was upregulated using cAMP. Diluted apolipoprotein B-depleted plasma was then added and liquid scintillation counting used to quantify the percentage of radioactive cholesterol from the cells effluxed into the media. To minimize variation related to batch effects, paired baseline and 12-month samples from cases and matched controls were included on the same plate for efflux capacity assessment. In addition, a pooled plasma control was used to correct for interassay variation across assays. In a pilot analysis involving blinded duplicate assessments of 20 patient samples divided into 2 aliquots, the mean intra-and interassay coefficients of variation were 3.7% and 4.7%, respectively. Lipoprotein-associated phospholipase A 2 activity levels were measured using an automated enzyme assay system. 25 HDL-related phenotypes, including cholesterol efflux capacity, were measured at both baseline and after 12 months of therapy in individuals with samples available.
Statistical Analysis
Medians, 25th, and 75th percentiles were calculated for continuous variables. The significance of variation in cholesterol Odds ratios were calculated across tertiles as well as per standard deviation increment in each biomarker. Conditional logistic regression models accounting for the matched study design were further adjusted for age, race, randomized treatment group, smoking status, systolic blood pressure, body mass index, fasting glucose, LDL cholesterol level, logtransformed triglyceride level, and family history of premature coronary artery disease. P-values for trend were obtained by including tertile number as a variable in the regression model. Models analyzing on-statin biomarkers incorporated on-treatment values for LDL and log-transformed triglycerides. To preserve power while maintaining the matched case-control design, subgroup analyses were conducted by adding appropriate interaction terms to the models. Subgroup-specific linear regression parameters and odds ratios were calculated using combinations of main effect and interaction terms (online-only Data Supplement).
All P-values were 2-tailed, with a value <0.05 used to indicate statistical significance. Analyses were performed using R version 3.1 software (The R Project for Statistical Computing).
RESULTS
The study population included 1050 trial participants-525 controls, 314 cases who experienced the primary JUPITER trial end point, and 525 cases who experienced the expanded secondary end point inclusive of all-cause mortality (Table 1) . Those who experienced the primary JUPITER trial end point were more likely to have been allocated to placebo, had slightly lower body mass index, were more likely to report current smoking, and had higher baseline triglycerides. HDL cholesterol, apoA-I, and HDL particle number were each significantly lower in cases compared with controls. By contrast, no significant difference was noted in baseline cholesterol efflux capacity.
Baseline cholesterol efflux capacity was higher in female participants (Table 2 ) but did not appreciably vary according to treatment group, smoking status, family history of premature coronary artery disease, or presence of the metabolic syndrome. Moderate correlations were noted between efflux capacity and other HDL-related phenotypes ( Figure 1 and Table II in the online-only Data Supplement). LDL-related biomarkers demonstrated modest correlations with cholesterol efflux capacity, with Spearman correlation coefficients of 0.19, 0.15, and 0.18 for non-HDL cholesterol, LDL cholesterol, and apolipoprotein B levels, respectively (P<0.0001 for each). HsCRP and lipoprotein-associated phospholipase A 2 activity levels, biomarkers of inflammation, both demonstrated inverse correlations with efflux capacity (Spearman correlation coefficients -0.09 and -0.21, respectively; P=0.003 and P<0.0001).
Overall, no significant association was found between baseline cholesterol efflux capacity and incident cardiovascular events, with adjusted odds ratios for tertiles 2 and 3 compared with tertile 1 of 1.08 (95% confidence interval [CI], 0.70-1.67) and 0.75 (95% CI, 0.47-1.21), respectively. Similarly, the adjusted odds ratio per SD increment in efflux capacity was not statistically significant-0.89 (95% CI, 0.72-1.10; P=0.28) ( Table 3 and Figure 2 ). No significant heterogeneity of effect was noted according to sex, randomization to rosuvastatin versus placebo, or in participants stratified according to median hsCRP levels or other clinical subgroups (Table  III in the online-only Data Supplement). The efficacy of rosuvastatin was also similar across tertiles of baseline cholesterol efflux capacity (Table IV in the online-only Data Supplement).
Twelve-month levels of cholesterol efflux capacity were available in 617 of 1050 (59%) study participants. Rosuvastatin treatment compared with placebo did not lead to a significant change in cholesterol efflux capacity (Table 4) . By contrast, a modest increase in HDL cholesterol, apoA-I, and HDL particle number levels was noted in individuals randomized to rosuvastatin treat- On-statin levels of cholesterol efflux capacity were available for 248 of 450 (55%) of rosuvastatin-treated study participants (Table VII in the online-only Data Supplement). On-statin cholesterol efflux capacity was significantly associated with risk of incident cardiovascular events for the primary end point (odds ratio per SD increment, 0.62; P=0.02) but not for the expanded end point inclusive of total mortality (odds ratio per SDincrement, 0.79; P=0.13) ( Table 5 and Figure 2) . No significant heterogeneity of effect was noted across clinical or biomarker parameters (Table VIII in the online-only Data  Supplement) .
Among HDL-related biomarkers assessed at baseline, HDL particle number had the strongest inverse association with incident cardiovascular events, followed by HDL cholesterol and apoA-I levels ( Figure 2 and Table IX in Figure 1 . Spearman correlations among HDL-related biomarkers.
Distributions for each biomarker and pairwise Spearman correlation coefficients and scatterplots are displayed. ApoA-I indicates apolipoprotein A-I; HDL-C, high-density lipoprotein cholesterol; HDLP, high-density lipoprotein particle number; and efflux capacity, cholesterol efflux capacity.
4 HDL-related biomarkers suggested an inverse association with incident events, HDL particle number emerged as the strongest inverse predictors of incident events ( Figure 2 , Table 6 , and Table X in the online-only Data Supplement). Effect estimates for baseline and on-treatment associations were similar in a sensitivity analysis to cases (N=182) with an incident hard cardiovascular event of myocardial infarction, stroke, or cardiovascular death. It is important to note that the magnitude of association for these biomarkers compares favorably to that observed for non-HDL cholesterol, a frequently used surrogate for atherogenic apolipoprotein-B-containing lipoproteins. For example, in a model adjusting for age, treatment, race, systolic blood pressure, smoking, body mass index, and fasting glucose, an odds ratio per SD lower non-HDL cholesterol of 0.73 (95% CI, 0.53-1.00; P=0.05) was observed.
Inclusion of alternate HDL-related biomarkers in the same regression model was used to isolate independent predictors of residual risk for incident cardiovascular events (Table 6 ). In this analysis, the inverse association between HDL particle number levels and incident CVD was the most robust and maintained significance in each of the mutually adjusted models.
DISCUSSION
In a nested case-control study in the JUPITER trial of participants with elevated hsCRP but normal or low LDL cholesterol, we determined the relationship among 4 key markers of HDL metabolism-HDL cholesterol, apoA-I, HDL particle number, and cholesterol efflux capacityand risk of incident CVD. An inverse relationship was noted for on-statin, but not baseline, cholesterol efflux capacity and incident cardiovascular events. Among all 4 HDL-related phenotypes analyzed, HDL particle number emerged as the strongest inverse predictor of incident events, at both baseline and during potent statin therapy.
Our findings of moderate correlations between cholesterol efflux capacity and HDL cholesterol levels, apoA-I, and HDL particle number are in keeping with multiple previous reports. [15] [16] [17] We extend these observations to note an inverse association between cholesterol efflux capacity and the inflammatory biomarkers hsCRP and lipoprotein-associated phospholipase A 2 activity. This finding is consistent with previous mouse and human data suggesting that remodeling of the HDL proteome or site-specific oxidation of apolipoprotein A-I by myeloperoxidase in an inflammatory CI indicates confidence interval; OR, odds ratio; and P trend, P value for linear trend across tertiles. Model 1: Conditional logistic regression odds ratio adjusted for age and treatment group. Model 2: Odds ratio adjusted for age, treatment group, race, smoking status, systolic blood pressure, body mass index, fasting glucose, baseline low-density lipoprotein cholesterol level, baseline log-transformed triglyceride level, and family history of premature coronary artery disease.
setting inhibits cholesterol efflux and the reverse cholesterol transport pathway. [26] [27] [28] Rosuvastatin was associated with an increase in HDL cholesterol, apoA-I, and HDL particle number as previously reported, 12 but it had no impact on cholesterol efflux capacity, consistent with a similar result noted in a randomized trial involving pravastatin or atorvastatin. 15 In contrast with most previous studies, [15] [16] [17] [18] we did not observe a significant inverse relationship between baseline cholesterol efflux capacity and incident cardiovascular events in JUPITER. One potential explanation for this directionally consistent but less striking relationship may relate to the elevated hsCRP for all JUPITER participants. The drivers of atherosclerotic events in this inflammatory context may be different than those in previous population-based studies. [15] [16] [17] [18] [19] It is interesting to note that on-statin cholesterol efflux capacity was inversely associated with incident cardiovascular events. This finding could reflect the increased importance of HDL functionality in the context of a low-achieved LDL cholesterol or during statin therapy. Although not conclusive, this association supports ongoing efforts to incorporate therapies that promote reverse cholesterol transport into statin-based regimens to improve patient outcomes.
The current study findings add to a growing body of evidence supporting HDL particle number as a stronger predictor of incident cardiovascular events than HDL cholesterol or apoA-I levels. Similar observations were noted from less contemporary population cohorts [6] [7] [8] and clinical trial-based analyses. [9] [10] [11] [12] In the Women's Health Study, a significant inverse relationship was noted with incident coronary events 29 but not for overall cardiovascular outcomes. 30 The present study extends this previous evidence base, noting that HDL particle number was the strongest HDL-related biomarker of residual risk in participants treated with potent statin therapy. In addition, we note that HDL particle number was a better risk predictor than the best-validated metric of HDL functionality, cholesterol efflux capacity. If confirmed in additional studies, HDL particle number assessment may have value as a surrogate for clinical efficacy in the assessment of interventions targeting HDL metabolism. This nuclear magnetic resonance -based assessment affords considerable logistical advantages over cholesterol efflux capacity, a cell-based assay that requires significant resources and is difficult to standardize across studies or research groups.
Strengths of the study include detailed assessment of 4 HDL-related phenotypes in a contemporary clinical trial population, prospective adjudication of all trial end points, and randomized allocation of potent statin therapy to achieve low levels of circulating LDL cholesterol. A limitation of this study is that the JUPITER trial was terminated after a median follow-up of 1.9 years on the basis of demonstrated efficacy of rosuvastatin therapy in cardiovascular event reduction. 20 The relatively small number of CVD events may have limited power to detect associations between HDL related phenotypes and outcomes, particularly in analyses restricted to those receiving rosuvastatin therapy. Furthermore, the generalizability of our findings may be limited beyond the population studied in the JUPI-TER trial. 
Mean (SD)
55 (17) 169 (35) 34 (7) 14 (4) 55 (17) 168 (35) 33 (7) 14 (4) 0.4 0 .6 0. 
CONCLUSIONS
On-statin but not baseline cholesterol efflux capacity was inversely associated with incident cardiovascular events in JUPITER trial participants. Among 4 HDL-related biomarkers, HDL particle number was the strongest inverse predictor of risk in both baseline and on-statin analyses. Whether a therapy designed to enhance cholesterol efflux capacity or increase HDL particle number can complement high-potency statin therapy in reducing cardiovascular risk remains to be determined.
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